Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Blinded Treatment Phase	STARTED	Zoledronic Acid	859
Blinded Treatment Phase	STARTED	Denosumab	859
Blinded Treatment Phase	Received Treatment	Zoledronic Acid	852
Blinded Treatment Phase	Received Treatment	Denosumab	850
Blinded Treatment Phase	COMPLETED	Zoledronic Acid	541
Blinded Treatment Phase	COMPLETED	Denosumab	555
Blinded Treatment Phase	NOT COMPLETED	Zoledronic Acid	318
Blinded Treatment Phase	NOT COMPLETED	Denosumab	304
Open Label Treatment Phase	STARTED	Zoledronic Acid	418
Open Label Treatment Phase	STARTED	Denosumab	426
Open Label Treatment Phase	COMPLETED	Zoledronic Acid	227
Open Label Treatment Phase	COMPLETED	Denosumab	233
Open Label Treatment Phase	NOT COMPLETED	Zoledronic Acid	191
Open Label Treatment Phase	NOT COMPLETED	Denosumab	193

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01345019/flow